Levi & Korsinsky, LLP announces that a KDMN class action lawsuit has been filed on behalf of investors who purchased Kadmon Holdings, Inc. (KDMN) securities between October 1, 2020 – March 10, 2021. For more on the KDMN Lawsuit please contact us today.

According to the Kadmon lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Belumosudil NDA was incomplete and/or deficient; (ii) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (iii) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (iv) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE KDMN CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Kadmon you have until June 2, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com